

Promonitor (and alternative technologies identified during scoping) for monitoring response to biologic treatment for rheumatoid arthritis

Promonitor (Grifols) is a portfolio of enzyme linked immunosorbent assays (ELISAs) that measure drug levels (etanercept, infliximab, infliximab biosimilars, adalimumab, rituximab, golimumab) and their correlating anti-drug antibodies (anti-etanercept, anti-infliximab, anti-adalimumab, anti-rituximab, anti-golimumab). The Promonitor portfolio of assays is intended to monitor response to biologic treatments for rheumatoid arthritis. It can be used alongside inflammatory markers and assessment tools such as the disease activity score 28 to enhance clinical decision making and optimise treatment regimens. Use of Promonitor may help clinicians to: predict loss of response to treatment, adjust treatment dose, and decide when to switch or stop treatment, without having any detrimental effect on clinical outcomes. It could also lead to improved quality of life for patients and reduced prescribing costs for the NHS. The NICE Diagnostics Assessment Programme will assess the clinical and cost-effectiveness of Promonitor (and alternative technologies identified during scoping) in order to make recommendations on their use in the NHS.